腺氨酸激酶 (SYK):一种新兴的目标,用于组装小分子抗瘤剂
Charanjit Kaur1, Amandeep Thakur2, Ke-Chi Liou2
1School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India.
Expert opinion on investigational drugs
|August 3, 2024
概括
腺氨酸激酶 (SYK) 在癌细胞存活和分裂中至关重要,特别是在B细胞恶性瘤中. 抑制SYK可以诱导癌细胞死亡,但临床转化和毒性仍然存在挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 腺氨酸激酶 (SYK) 是一种非受体氨酸激酶,与癌细胞存活和增殖有关.
- 在各种B细胞恶性瘤中观察到构成性SYK激活,其抑制会触发亡.
- 在某些情况下,SYK还可以作为瘤抑制剂.
研究的目的:
- 审查SYK在特定癌症的进展中的作用,包括慢性淋巴细胞白血病 (CLL),扩散性大B细胞淋巴瘤 (DLBCLs),急性髓性白血病 (AML) 和多发性髓瘤 (MM).
- 讨论针对SYK在癌症治疗中的当前和新兴治疗策略.
- 突出SYK抑制剂开发中的挑战,并倡导新的结构模板.
主要方法:
- 关于SYK在癌症中的作用的文献综述.
- 分析涉及SYK抑制剂的治疗策略.
- 讨论临床前临床转化挑战和毒性概况.
主要成果:
- SYK在几种血液性恶性瘤的发病过程中发挥着重要作用.
- 目前正在研究针对SYK的各种治疗策略,包括新型抑制剂和组合疗法.
- 从临床前研究转化到临床研究的不良转化率和剂量限制性毒性是SYK抑制剂开发的主要障碍.
结论:
- 开发新的SYK抑制结构模板对于推进癌症治疗至关重要.
- 需要跨学科的努力来扩大有效的SYK抑制剂的武器库.
- 解决临床转化和毒性方面的挑战对于成功的SYK向治疗至关重要.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:26Receptor Tyrosine Kinases
12.5K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.5K
01:00Enzyme-linked Receptors
77.8K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.8K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K